BioCentury | Jan 8, 2021
Emerging Company Profile

Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer

Myeloid is engineering monocytes as cellular cancer therapies by programming pluripotent myeloid cells to target tumor cells and conduct a suite of myeloid antitumor functions. Ronald Vale and Siddhartha Mukherjee are among the founders of...
BioCentury | Oct 13, 2020
Finance

Oct. 13 Quick Takes: Sovereign wealth fund backs Evotec; plus Canaan, EdiGene, Cedilla, Rappta and Lassogen

UAE fund, Novo invest €250M in EvotecEvotec SE (Xetra:EVT) raised €250 million ($295.5 million) via a private placement in which it sold shares to Mubadala Investment Co. and Novo Holdings A/S. Mubadala, a United Arab Emirates...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Targeting the PP2A-STRN3 interaction to treat gastric cancer

DISEASE CATEGORY: Cancer INDICATION: Gastric cancer Interrupting the interaction between PP2A catalytic subunit PPP2CA and STRN3, a regulatory subunit, could treat gastric cancer. In patients, STRN3 expression...
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

The idea of sending disease-driving proteins to the cell’s garbage can is only the first act in a field that now centers around targeted degradation. In the sequel, researchers are extending the principle to other...
BioCentury | Aug 29, 2019
Translation in Brief

Cytomegalovirus vectors for a prophylactic HIV vaccine

A spread-deficient cytomegalovirus carrying SIV antigens evoked long-term protective immunity against successive SIV infections in monkeys, suggesting that a prophylactic HIV vaccine can be developed in humans using a similar strategy. While academics and companies...
BioCentury | Aug 28, 2019
Politics & Policy

Aug. 28 P&P Quick Takes: Liver failure warning for HCV drugs; plus FDA guidances and more

Liver failure linked to HCV drugs FDA said it has identified 63 incidences of worsening liver function, including cases of liver failure and death, in patients with liver impairment taking HCV drugs Mavyret glecaprevir/pibrentasvir from...
BioCentury | Aug 23, 2019
Politics & Policy

Aug. 23 P&P Quick Takes: FDA meetings on pediatric safety of OxyContin, Singulair; a vaccine meeting on Chikungunya

FDA panels to discuss pediatric safety of OxyContin, Singulair On Sept. 26 and 27, a joint meeting of FDA's Pediatric Advisory Committee and the Drug Safety and Risk Management Advisory Committee will discuss pediatric studies...
BioCentury | Aug 12, 2019
Politics & Policy

Aug. 12 P&P Quick Takes: China to implement ethics committee; plus Senators call for action on AveXis and FDA’s Fabry guidance

China planning national science, technology ethics committee China’s central committee for deepening overall reform approved a plan to establish a national science and technology ethics committee. The government said the committee is meant to improve...
BioCentury | Aug 2, 2019
Politics & Policy

Aug. 2 P&P Quick Takes: Pediatric disease voucher guidance clarified, CMS proposes rule on hospital price transparency and draft guidance on clinical trial prac

Update to pediatric disease guidance clarifies what qualifies FDA updated its draft guidance on rare pediatric disease priority review vouchers to include provisions from the Advancing Hope Act of 2016 and the 21st Century Cures...
BioCentury | Jul 27, 2019
Politics & Policy

July 25 P&P Quick Takes: NIH releases more restrictive rules on fetal tissue use; plus SOX, China drug inspections and more

NIH raises bar for use of fetal tissue in research NIH released details Friday on new rules for the use of fetal tissue in extramural research that require scientists to justify to an ethics advisory...
Items per page:
1 - 10 of 282